- US12473353utility2025Antigen-binding Molecule, a Pharmaceutical Composition, and a Method0 cites
- US12473375utility2025Methods for Controlling Blood Pharmacokinetics of Antibodies0 cites
- US12460014utility2025Antibody-containing Preparation0 cites
- US12441735utility2025Nitrogen-containing Heterocyclic Compound Having NRF2 Activation Effect0 cites
- US12435137utility2025Antigen-binding Molecule Containing Two Antigen-binding Domains That Are Linked to Each Other0 cites
- US12435147utility2025Nemolizumab in the Treatment of Atopic Dermatitis with Moderate to Severe Excoriation0 cites
- US12421322utility2025Antibody Variant and Isoform with Lowered Biological Activity0 cites
- US12415835utility2025Peptide-compound Cyclization Method0 cites
- US12415857utility2025Anti-ctla-4 Antibody and Use Thereof0 cites
- US12410212utility2025Cyclic Compound Having Selective KRAS Inhibitory Effect on HRAS and NRAS0 cites
- US12410168utility2025Pyrazolopyridine Derivative Having GLP-1 Receptor Agonist Effect0 cites
- US12404299utility2025Method for Producing Peptide Compound Comprising Highly Sterically Hindered Amino Acid0 cites
- US12391971utility2025Method for Synthesizing Peptides in Cell-free Translation System0 cites
- US12379357utility2025Method for Quantifying Amino Group-containing Compound Protected by Protecting Group Having Fmoc Skeleton0 cites
- US12371454utility2025Cyclic Peptide Compound Having Kras Inhibitory Action0 cites
- US12371483utility2025Cross-species Anti-latent Tgf-beta 1 Antibodies and Methods of Use0 cites
- US12371485utility2025Antigen-binding Molecule Inducing Immune Response to Target Antigen0 cites